Heparin-Induced Thrombocytopenia, Fifth Edition (Fundamental and Clinical Cardiology)

Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most frequent and devastating adverse drug reactions encountered by physicians. This thoroughly updated fifth edition from international experts Professors Warkentin and Greinacher is the gold standard for accurate diagnosis and management of this cond Annotation Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most devastating and frequent adverse drug reactions encountered by physicians. This thoroughly updated fifth edition from international experts Professors Warkentin and Greinacher is the gold standard for accurate diagnosis and management of heparin-induced thrombocytopenia. By identifying key signs and symptoms and providing clear intervention strategies, including detailed information on the use of alternative anticoagulants to manage critical circumstances, this is an essential resource for all clinicians and a must for hematology consultants. The fifth edition includes;Coverage of approved and novel pharmacotherapies, current dosing guidelines, and the advantages and limitations of alternative anticoagulants, Review of the immune basis and pathogenesis, animal models, and laboratory testing for HIT antibodies, Description of clinical features, differential diagnosis, scoring systems, and frequency of HIT in diverse clinical settings--including pediatric patients--and provides evidence-based guidelines for the recognition, treatment, and prevention of this disorder, Detailed actions that should and should not be taken after the identification of heparin-induced thrombocytopenia, Selection criteria from a variety of new treatment options, helping physicians determine which of these agents are safe and effective for their patients, A comprehensive overview of clinical and laboratory studies on heparin-induced thrombocytopenia Suitable for clinicians and hematology consultants, this title includes: coverage of approved and novel pharmacotherapies, dosing guidelines, and the advantages and limitations of alternative anticoagulants; review of the immune basis and pathogenesis, animal models, and laboratory testing for HIT antibodies; and more. Chapter 22: A clinician's perspective on heparin-induced thrombocytopenia: Paradoxes, myths, and continuing challenges -- Appendices -- Index -- Back Cover